ReShape announces shareholder approval of Vyome merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Should l Buy ?
Merger Approval: ReShape Lifesciences' shareholders have approved the merger with Vyome Therapeutics, set to take effect on August 15, 2025, with trading under the new name Vyome Holdings, Inc. on Nasdaq.
Future Prospects: Vyome aims to build a healthcare platform between the US and India, with leadership expressing confidence in creating shareholder value as they transition to a public company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
